Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites can significantly impact the success of immune checkpoint inhibitors (ICIs) in treating colorectal cancer. By understanding these mechanisms, researchers are developing novel personalized immunotherapy strategies that target the gut microbiome to optimize treatment efficacy.

Key Takeaways:

• The gut microbiota plays a crucial role in modulating the efficacy of immune checkpoint inhibitors (ICIs) in treating colorectal cancer.
• Specific bacterial species, such as Lactobacillus paracasei and Fusobacterium nucleatum, can regulate ICIs efficacy by modulating antigen presentation or the tumor immune microenvironment.
• Microbial metabolites, such as short-chain fatty acids (SCFAs), can enhance immune function and improve ICIs outcomes.
• Potential microbiome-targeted interventions, including probiotic/prebiotic combinations, optimized antibiotic administration timing, refined fecal microbiota transplantation (FMT) protocols, and engineered synthetic biology-based bacterial therapies, are being developed to enhance ICIs efficacy.
• The study highlights the importance of personalized immunotherapy strategies that take into account the unique gut microbiome composition of individual patients.
• Researchers, including Yingkun Yue, Jing Li, Jiaxin Pan, and Fang Liang, have been working tirelessly to develop these novel strategies, which hold promise for improving treatment outcomes for colon cancer patients.

Statistics:

• Colorectal cancer is the third leading cause of cancer-related deaths worldwide, with approximately 1.8 million new cases diagnosed each year (GLOBOCAN, 2020).
• Less than 20% of patients with metastatic colorectal cancer achieve 5-year survival rates with conventional treatments (ASCO, 2020).
• The gut microbiome plays a crucial role in modulating immune function, with alterations in gut microbiota composition associated with an increased risk of colorectal cancer (Huang, 2018).
• Immune checkpoint inhibitors (ICIs) have shown significant clinical benefits in treating various malignancies, including colorectal cancer, with response rates ranging from 10-30% (Garcia-Castellon, 2020).

Sources:

• Biochimica et Biophysica Acta (2025):189476.
• NewsRx (2025). New Colon Cancer Study Findings Recently Were Reported by Researchers at Zhengzhou Central Hospital Affiliated to Zhengzhou University (Research progress on gut microbiota in colorectal cancer immunotherapy). Cancer Weekly. November 4, 2025; p 1099.